A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine.

[1]  H. Jick,et al.  Measles in the United Kingdom 1990-2008 and the effectiveness of measles vaccines. , 2010, Vaccine.

[2]  R. Vierkant,et al.  Predominant inflammatory cytokine secretion pattern in response to two doses of live rubella vaccine in healthy vaccinees. , 2010, Cytokine.

[3]  D. Sugerman,et al.  Measles Outbreak in a Highly Vaccinated Population, San Diego, 2008: Role of the Intentionally Undervaccinated , 2010, Pediatrics.

[4]  J. Snyder,et al.  Measles control--can measles virus inhibitors make a difference? , 2009, Current opinion in investigational drugs.

[5]  R. Vierkant,et al.  Gender effects on humoral immune responses to smallpox vaccine. , 2009, Vaccine.

[6]  Stephen L. Cochi,et al.  Global measles mortality, 2000-2008. , 2009, MMWR. Morbidity and mortality weekly report.

[7]  R. Vierkant,et al.  Associations between cytokine/cytokine receptor single nucleotide polymorphisms and humoral immunity to measles, mumps and rubella in a Somali population. , 2008, Tissue antigens.

[8]  I. Cook.  Sexual dimorphism of humoral immunity with human vaccines. , 2008, Vaccine.

[9]  A. Bennett,et al.  Laboratory methods for assessing vaccine potency retained in aerosol outputs from nebulizers: application to World Health Organization measles aerosol project. , 2008, Vaccine.

[10]  Development of a Novel Efficient Fluorescence-Based Plaque Reduction Microneutralization Assay for Measles Virus Immunity , 2008, Clinical and Vaccine Immunology.

[11]  R. Vierkant,et al.  Human Leukocyte Antigen and Cytokine Receptor Gene Polymorphisms Associated With Heterogeneous Immune Responses to Mumps Viral Vaccine , 2008, Pediatrics.

[12]  D. Gust,et al.  Measles Outbreak Associated with a Church Congregation: A Study of Immunization Attitudes of Congregation Members , 2008, Public health reports.

[13]  Measles--United States, January 1-April 25, 2008. , 2008, MMWR. Morbidity and mortality weekly report.

[14]  N. Andrews,et al.  Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. , 2007, Vaccine.

[15]  W. Bellini,et al.  Seroprevalence of measles antibody in the US population, 1999-2004. , 2007, The Journal of infectious diseases.

[16]  D. Bi,et al.  Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. , 2007, Archives of pediatrics & adolescent medicine.

[17]  J. Leitner,et al.  Ethnic differences in plasma levels of interleukin-8 (IL-8) and granulocyte colony stimulating factor (G-CSF). , 2007, Translational research : the journal of laboratory and clinical medicine.

[18]  Scott M. Williams,et al.  Ethnic differences in cytokine gene polymorphisms: potential implications for cancer development , 2007, Cancer Immunology and Immunotherapy.

[19]  D. Bernstein,et al.  Variability and gender differences in memory T cell immunity to varicella-zoster virus in healthy adults. , 2006, Vaccine.

[20]  P. Quinlisk,et al.  Update: multistate outbreak of mumps--United States, January 1-May 2, 2006. , 2006, MMWR. Morbidity and mortality weekly report.

[21]  A. Plasència,et al.  Seroprevalence of measles, rubella, and mumps antibodies in Catalonia, Spain: results of a cross-sectional study , 2006, European Journal of Clinical Microbiology and Infectious Diseases.

[22]  N. Andrews,et al.  Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay. , 2006, Journal of virological methods.

[23]  M. Guzmán,et al.  Race: a risk factor for dengue hemorrhagic fever , 2006, Archives of Virology.

[24]  R. Vierkant,et al.  Inter‐operator variation in ELISPOT analysis of measles virus‐specific IFN‐γ‐secreting T cells , 2005 .

[25]  R. Vierkant,et al.  Inter-operator variation in ELISPOT analysis of measles virus-specific IFN-gamma-secreting T cells. , 2005, Scandinavian journal of clinical and laboratory investigation.

[26]  Y. Maldonado,et al.  Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. , 2004, The Journal of infectious diseases.

[27]  D. Harlan,et al.  Ethnicity Greatly Influences Cytokine Gene Polymorphism Distribution , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  R. Vierkant,et al.  Association of parental vaccination reports with measles, mumps, and rubella protective antibody levels: comparison of Somali immigrant, Hispanic migrant, and US children in Rochester, Minn. , 2002, Mayo Clinic proceedings.

[29]  R. Pebody,et al.  Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. , 2002, Vaccine.

[30]  C. Muller,et al.  Neutralizing B cell response in measles. , 2002, Viral immunology.

[31]  R. Vierkant,et al.  Identification of an association between HLA class II alleles and low antibody levels after measles immunization. , 2001, Vaccine.

[32]  Y. Maldonado,et al.  Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. , 2001, The Journal of infectious diseases.

[33]  J. Goedert,et al.  Racial differences in HLA class II associations with hepatitis C virus outcomes. , 2001, The Journal of infectious diseases.

[34]  J. Mossong,et al.  Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. , 2000, Vaccine.

[35]  M. Shohat,et al.  Gender differences in the reactogenicity of measles-mumps-rubella vaccine. , 2000, The Israel Medical Association journal : IMAJ.

[36]  H. Whittle,et al.  Sex-Associated Differences in the Antibody-Dependent Cellular Cytotoxicity Antibody Response to Measles Vaccines , 2000, Clinical Diagnostic Laboratory Immunology.

[37]  L. Mitchell.  Sex differences in antibody- and cell-mediated immune response to rubella re-immunisation. , 1999, Journal of medical microbiology.

[38]  J. Mossong,et al.  Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. , 1999, American journal of epidemiology.

[39]  B. Ward,et al.  Measurement of measles virus-specific neutralizing antibodies: evaluation of the syncytium inhibition assay in comparison with the plaque reduction neutralization test. , 1999, Diagnostic microbiology and infectious disease.

[40]  P. Wollan,et al.  Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects. , 1999, Vaccine.

[41]  A. Charlett,et al.  An evaluation of nine commercial EIA kits for the detection of measles specific IgG. , 1997, Journal of virological methods.

[42]  V. Gadag,et al.  Immunity against measles in school-aged children: implications for measles revaccination strategies. , 1996, Canadian journal of public health = Revue canadienne de sante publique.

[43]  D. Nalin,et al.  Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. , 1996, The Pediatric infectious disease journal.

[44]  B. Ward,et al.  Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. , 1995, The Journal of infectious diseases.

[45]  V. Gadag,et al.  Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody , 1995, Journal of clinical microbiology.

[46]  H. Whittle,et al.  Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal , 1995, The Pediatric infectious disease journal.

[47]  Manfred S. Green,et al.  Sex differences in the humoral antibody response to live measles vaccine in young adults. , 1994, International journal of epidemiology.

[48]  B. Christenson,et al.  Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. , 1994, Vaccine.

[49]  W. Orenstein,et al.  Persistence of measles antibody after revaccination. , 1992, The Journal of infectious diseases.

[50]  Robert T. Chen,et al.  Measles antibody: reevaluation of protective titers. , 1990, The Journal of infectious diseases.

[51]  W. Orenstein,et al.  The plaque-neutralization test as a measure of prior exposure to measles virus. , 1987, The Journal of infectious diseases.

[52]  P. Albrecht,et al.  Role of virus strain in conventional and enhanced measles plaque neutralization test. , 1981, Journal of virological methods.